Efficacy and Safety of Ruxolitinib Cream in Pediatric Atopic Dermatitis: TRuE-AD3 Study Findings

A phase 3 study (TRuE-AD3) evaluated the efficacy and safety of ruxolitinib cream in children aged 2-11 years with mild-to-moderate atopic dermatitis (AD). A total of 330 children were randomized to receive either vehicle, 0.75%, or 1.5% ruxolitinib cream twice daily for 8 weeks.

The primary endpoint was achieving Investigator's Global Assessment treatment success (IGA-TS) at Week 8. Results showed that significantly more children achieved IGA-TS with the 0.75% (36.6%) and 1.5% (56.5%) ruxolitinib creams compared to vehicle (10.8%; P < 0.0001). Improvements in itch and quality of life were also noted, with a safety profile consistent with previous studies in adolescents and adults.

In conclusion, ruxolitinib cream demonstrated superior efficacy compared to vehicle in improving AD symptoms in this pediatric population and was well-tolerated.

For a link to the original article, click HERE

Elevate-Alliance Editorial Committee